Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC

Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC

Introduction: BRAF mutations are rare in patients with NSCLC, and treatment options are limited. Dabrafenib plus trametinib (dab-tram) was approved for BRAFV600-mutated advanced NSCLC (aNSCLC), based on results from a phase 2 study (NCT01336634). This retrospective analysis compared the effectivenes...

Full description

Bibliographic Details
Main Authors: Bruce E. Johnson, MD, Christina S. Baik, MD, Julien Mazieres, MD, Harry J.M. Groen, MD, Barbara Melosky, MD, Jürgen Wolf, MD, Fatemeh Asad Zadeh Vosta Kolaei, PhD, Wen-Hsing Wu, MS, Stefanie Knoll, PhD, Meryem Ktiouet Dawson, MD, Adam Johns, PhD, David Planchard, MD
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:JTO Clinical and Research Reports
Subjects:
BRAF inhibitor
MEK inhibitor
BRAF-mutated aNSCLC
Indirect comparison
Platinum-based chemotherapy
Immune-checkpoint inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322000480

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322000480

Similar Items